The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease
暂无分享,去创建一个
Frederik Barkhof | Johannes Kornhuber | Philip Scheltens | Henne Holstege | Frank Jessen | Alfredo Ramirez | Jens Wiltfang | Wiesje M. Van der Flier | Pieter Jelle Visser | Tim Becker | John C. van Swieten | Carlos Cruchaga | Oliver Peters | Charlotte E. Teunissen | F. Jessen | P. Scheltens | F. Barkhof | P. Visser | T. Becker | Y. Pijnenburg | J. Kornhuber | J. Wiltfang | C. Cruchaga | W. Flier | A. Ramírez | O. Peters | E. Louwersheimer | H. Holstege | C. Teunissen | J. Swieten | Yolande A.L. Pijnenburg | Stefanie Heilmann | Eva Louwersheimer | S. Heilmann
[1] Thomas W. Mühleisen,et al. Erratum: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2009, Nature Genetics.
[2] P. Scheltens,et al. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability , 1995, Journal of Neurology.
[3] A. Fagan,et al. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. , 2010, Journal of Alzheimer's disease : JAD.
[4] F. Jessen,et al. Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.
[5] Nick C Fox,et al. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele , 2011, The Lancet Neurology.
[6] T. Kudo,et al. SORL1 is genetically associated with Alzheimer disease in a Japanese population , 2009, Neuroscience Letters.
[7] Sandro Sorbi,et al. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. , 2011, Archives of neurology.
[8] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[9] Tim Becker,et al. INTERSNP: genome-wide interaction analysis guided by a priori information , 2009, Bioinform..
[10] F. Jessen,et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. , 2013, Biochemical pharmacology.
[11] K. Lunetta,et al. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. , 2008, Archives of neurology.
[12] R. Mayeux,et al. Endophenotypes in normal brain morphology and Alzheimer's disease: a review , 2009, Neuroscience.
[13] F. Jessen,et al. Influence of SORL1 gene variants: Association with CSF amyloid-β products in probable Alzheimer's disease , 2008, Neuroscience Letters.
[14] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[15] L. Kiemeney,et al. Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.
[16] Nick C Fox,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.
[17] Y. Teo,et al. SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese , 2009, Neurobiology of Aging.
[18] K. Blennow,et al. Sequence variation in SORL1 and dementia risk in Swedes , 2010, neurogenetics.
[19] W. M. van der Flier,et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.
[20] A. Levey,et al. Loss of LR11/SORLA Enhances Early Pathology in a Mouse Model of Amyloidosis: Evidence for a Proximal Role in Alzheimer's Disease , 2008, The Journal of Neuroscience.
[21] Nick C Fox,et al. The effect of APOE genotype on clinical phenotype in Alzheimer disease , 2006, Neurology.
[22] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[23] T. Montine,et al. LR11/SorLA Expression Is Reduced in Sporadic Alzheimer Disease but not in Familial Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.
[24] A. Kurz,et al. Impact of SORL1 Single Nucleotide Polymorphisms on Alzheimer’s Disease Cerebrospinal Fluid Markers , 2011, Dementia and Geriatric Cognitive Disorders.
[25] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[26] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[27] W. M. van der Flier,et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia , 2013, Neurology.
[28] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[29] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. H. Lee,et al. ASSOCIATION BETWEEN GENETIC VARIANTS IN SORL1 AND AUTOPSY-CONFIRMED ALZHEIMER DISEASE , 2008, Neurology.
[31] Paul M. Thompson,et al. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease , 2011, NeuroImage.
[32] Eden R Martin,et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. , 2009, American journal of human genetics.
[33] P. Madsen,et al. Activation and Functional Characterization of the Mosaic Receptor SorLA/LR11* , 2001, The Journal of Biological Chemistry.
[34] Sudha Seshadri,et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.
[35] W. M. van der Flier,et al. SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. , 2014, Human molecular genetics.
[36] S. Heath,et al. Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study. , 2010, Journal of Alzheimer's disease : JAD.
[37] P. Vliet. Cholesterol and Late-Life Cognitive Decline , 2012 .
[38] Timo Grimmer,et al. SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease , 2012, European Archives of Psychiatry and Clinical Neuroscience.
[39] K. Lunetta,et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.
[40] J. C. Pruessner,et al. Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI , 2006, Journal of Neurology.
[41] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[42] Frederik Barkhof,et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. , 2014, Journal of Alzheimer's disease : JAD.
[43] Yun Liu,et al. Amyloid-&bgr;-Related Genes SORL1 and ACE are Genetically Associated With Risk for Late-onset Alzheimer Disease in the Chinese Population , 2010, Alzheimer disease and associated disorders.
[44] Matthew H. Bailey,et al. GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease , 2013, Neuron.
[45] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[46] Michael Weiner,et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.
[47] Jason H. Moore,et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.
[48] F. Jessen,et al. Multicenter assessment of reliability of cranial MRI , 2006, Neurobiology of Aging.
[49] N. Hübner,et al. Identification of Alzheimer disease risk genotype that predicts efficiency of SORL1 expression in the brain. , 2012, Archives of Neurology.
[50] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[51] Henrik Zetterberg,et al. APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 , 2004, Neurology.
[52] M. Owen,et al. SORL1 variants and risk of late-onset Alzheimer’s disease , 2008, Neurobiology of Disease.
[53] W. M. van der Flier,et al. Most rapid cognitive decline in APOE ε4 negative Alzheimer's disease with early onset , 2009, Psychological Medicine.
[54] G. Walstra,et al. [CAMDEX-N: the Dutch version of the Cambridge Examination for Mental Disorders of the Elderly with automatic data processing]. , 1991, Tijdschrift voor gerontologie en geriatrie.
[55] C. Scriver. Allelic and Locus Heterogeneity , 2006 .
[56] J. Haines,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.
[57] P. S. St George-Hyslop,et al. Association between SORL1 and Alzheimer's disease in a genome-wide study , 2007, Neuroreport.
[58] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[59] R. Nixon. Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. , 2004, The American journal of pathology.
[60] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[61] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.